Riskpilot← Back to searchSign inGet full accessLAB 7 AS
ASActiveOrg 921883617Rambergveien 3, 7. Etasje, 3115 TønsbergManufacture of medical and dental instruments and supplies · NACE 3250Est. 20181 employees
Revenue 2023
NOK 2,3M
-13% vs 2022
EBITDA margin
-8.9%
-191% vs 2022
Equity ratio
42.3%
Financial strength
Net profit 2023
NOK -323K
-2665% vs 2022
| Revenue | NOK 2,3M | -13% |
| EBITDA | NOK -200K | -191% |
| Net profit | NOK -323K | -2665% |
| Total assets | NOK 987K | -38% |
| Equity | NOK 417K | -44% |
| Employees | 1 | — |
Legal name
LAB 7 AS
Org number
921883617
Legal form
Aksjeselskap
NACE code
3250 · Manufacture of medical and dental instruments and supplies
Founded
14. desember 2018
Share capital
NOK 100 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Å drive et tannkteknisk laboratorium, hvor det produseres tannerstatninger mv. På oppdrag fra tannleger, samt virksomhet som står i naturlig forbindelse med dette.
Address
Rambergveien 3, 7. Etasje, 3115 Tønsberg
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 2 706 | 3 158 | 3 146 | 2 588 | 2 257 |
| Staff expenses | −0 | −441 | −715 | −1 072 | −668 | −696 |
| EBITDA | −20 | 950 | 553 | 47 | 220 | −200 |
| Depreciation & amort. | −0 | −65 | −90 | −135 | −178 | −200 |
| EBIT | −20 | 886 | 462 | −88 | 42 | −400 |
| Net financials | 0 | −8 | −0 | −18 | −25 | −13 |
| Profit before tax | −20 | 877 | 462 | −106 | 17 | −413 |
| Tax | −8 | 193 | 104 | −22 | 4 | −89 |
| Net profit | −11 | 684 | 358 | −85 | 13 | −323 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Total assets | 408 | 1 571 | 1 446 | 1 741 | 1 588 | 987 |
| Equity | 370 | 455 | 813 | 728 | 741 | 417 |
| Long-term debt | 0 | 2 | 0 | 470 | 332 | 195 |
| Short-term debt | 38 | 1 114 | 633 | 543 | 515 | 375 |
| Total debt | 38 | 1 116 | 633 | 1 013 | 847 | 569 |
EBITDA margin
-8.9%
This company
15.8%
Market median
-156% vs market
20182023
Equity ratio
42.3%
This company
38.2%
Market median
+11% vs market
20182023
Return on equity
-77.5%
This company
18.4%
Market median
-521% vs market
20182023
Net profit margin
-14.3%
This company
8.1%
Market median
-277% vs market
20182023
Asset turnover
2.29×
This company
1.12×
Market median
+104% vs market
20182023
Debt / equity
1.36×
This company
0.62×
Market median
-119% vs market
20182023
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-11-16 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AI Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2018 | — | — | |
| Board of Directors | 2018 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Nurven As | Company | 50.0% | 50.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Nurven As
LAB 7 AS Board members of LAB 7 AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anke Isohuhta | Chief Executive Officer | 0 companies |
| Daniel Holck | Chairman | 0 companies |
| Silje Drege Løfsnæs | Board of Directors | 0 companies |
| Sigurd Schneider | Chairman | 0 companies |
| Pål-Espen Tannmand | Board of Directors | 0 companies |